Cantor Fitzgerald Starts Akero Therapeutics (AKRO) at Overweight, 'Positive on Upcoming F4 NASH Readout'
Tweet Send to a Friend
(Updated - September 19, 2023 6:13 AM EDT)
Cantor Fitzgerald analyst Prakhar Agrawal initiates coverage on Akero Therapeutics (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Cantor Fitzgerald analyst Prakhar Agrawal initiates coverage on Akero Therapeutics (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
